ライフサイエンスコーパス: vitamin D

1 d either with bisphosphonates or calcium and vitamin D.

2 ling pathways including Smads, TGF-beta, and vitamin D.

3 metabolism of glucose, lipid, phosphate and vitamin D.

4 elet count, 25(OH) vitamin D, or 1,25(di-OH) vitamin D.

5 n cancers and is also an important source of vitamin D.

6 o clear CVD risk reduction from supplemental vitamin D.

7 and WT/WT mice) after receiving a high dose vitamin D.

8 o use as well as serum levels of calcium and vitamin D.

9 ce demonstrates the importance of sufficient vitamin D (1alpha, 25-dihydroxyvitamin D3) levels during

10 radiation for conversion to ergocalciferol (vitamin D(2)) resulting in a yield of ergocalciferol tha

11 a 20-epi-Inhoffen-Lythgoe diol derived from vitamin D(2).

12 The major circulating metabolite of vitamin D (25-hydroxyvitamin D) is converted to the acti

13 ntraperitoneal administration of 1,25(OH)(2) vitamin D(3) (2 days, once per day) in wild-type and int

14 actorial trial of marine n-3 FAs (1 g/d) and vitamin D(3) (2000 IU/d) in the primary prevention of CV

15 idence of pulmonary tuberculosis between the vitamin D(3) (50 events in 1812 patients analysed) and p

16 d as wall materials for the encapsulation of vitamin D(3) (VD(3)).

17 The vitamin D(3) -induced increase of osteocalcin and osteop

18 increased VDR expression in the presence of vitamin D(3) .

19 how in this article that biologically active vitamin D(3) [1,25(OH)(2)-D(3)] significantly downregula

20 In contrast, 1,25(OH)(2) vitamin D(3) administration had no effect in Slc34a2-def

21 d with reduced molar ratios of 25(OH)D(3)-to-vitamin D(3) and increased molar ratios of 1alpha,25(OH)

22 CYP27B1 expression was not affected by vitamin D(3) and inflammatory conditions.

23 tal ligament cells (hPDLCs) are regulated by vitamin D(3) and play a fundamental role in periodontal

24 on of NaPi-IIb are stimulated by 1,25(OH)(2) vitamin D(3) but whether NaPi-IIb is the only target und

25 Vitamin B(12) and vitamin D(3) deficiencies are reported worldwide and co-

26 Although vitamin D(3) deficiency is considered as a risk factor f

27 We show that vitamin D(3) directly reduces FcepsilonRI expression on

28 cipants were randomly assigned to 1 of the 4 vitamin D(3) doses, and the best noncontrol dose for pre

29 ontent and decreased the bioaccessibility of vitamin D(3) due to the inhibition of micellization proc

30 In both groups, 1,25(OH)(2) vitamin D(3) elicited the expected increase of plasma fi

31 415 deaths were recorded: 211 in the vitamin D(3) group and 204 in the placebo group.

32 risk of hypercalcaemia (three events in the vitamin D(3) group and two events in the placebo group;

33 We hypothesized that vitamin D(3) impacts FcepsilonRI expression and addresse

34 A beneficial role of vitamin D(3) in AD is discussed to be important especial

35 water soluble vitamin B(12) and fat soluble vitamin D(3) in single product.

36 In both genotypes, 1,25(OH)(2) vitamin D(3) induced similar hyperphosphaturic responses

37 ve a weekly oral dose of either 14,000 IU of vitamin D(3) or placebo for 3 years.

38 e born to mothers who had received 400 IU of vitamin D(3) per day (control group).

39 born to mothers who had received 4400 IU of vitamin D(3) per day during pregnancy (vitamin D group)

40 We determined the effect of melanin on vitamin D(3) photosynthesis in healthy young volunteers

41 Vitamin D(3) plays a fundamental role in human health; h

42 The vitamin D(3) regimen did not increase the risk of hyperc

43 roxyvitamin D(3) (25[OH]D(3)) as a marker of vitamin D(3) status.

44 1,25(OH)(2) vitamin D(3) stimulates NaPi-IIb expression and function

45 d, double-blind, placebo-controlled trial of vitamin D(3) supplementation among adults living with HI

46 ted fall risk and low serum 25-(OH)D levels, vitamin D(3) supplementation at doses of 1000 IU/d or hi

47 s, which might mitigate the effectiveness of vitamin D(3) supplementation during periodontal treatmen

48 2001 patients were randomly assigned to the vitamin D(3) supplementation group, and 1999 to the plac

49 s of this study were to assess the effect of vitamin D(3) supplementation on the risk of mortality an

50 Additional research is needed before vitamin D(3) supplementation should be considered for im

51 1:1 to receive either weekly oral 50 000 IU vitamin D(3) supplements (cholecalciferol) for the first

52 first month of ART followed by daily 2000 IU vitamin D(3) supplements or a matching weekly and daily

53 ogy suggests that melanin inhibits cutaneous vitamin D(3) synthesis by UVR.

54 We report that administration of 1,25(OH)(2) vitamin D(3) to wild-type mice resulted in the expected

55 Serum concentrations of vitamin D(3), 25(OH)D(3), and 1alpha,25-dihydroxyvitamin

56 e 25(OH)D response to six oral doses of 3 mg vitamin D(3), administered over 1 year, differed between

57 th and biochemical composition of the cells (vitamin D(3), PUFAs and carotenoids) was evaluated.

58 to study the bioavailability of calcium and vitamin D(3), the W/O/W double emulsions were subjected

59 Fish have the highest natural content of vitamin D(3), which is suggested to originate from zoopl

60 ness about the general low dietary intake of vitamin D(3).

61 hich microalgal species may be the source of vitamin D(3).

62 UVB could be used as a new natural source of vitamin D(3,) either as direct source or through animal

63 Clearance of 25(OH)D before versus after vitamin-D(3) supplementation did not differ.

64 ere randomized to receive either: 1) 2000 IU vitamin D-3 (Vit D) per day; 2) 4000 mg CLA per day; 3)

65 importance of distal intestinal segments to vitamin D action.

66 ption of calcium; however, in animal studies vitamin D also increases the absorption of toxic metals,

67 ions of the DIO model, VDR activation by the vitamin D analog calcipotriol reduced liver inflammation

68 t, and they include topical corticosteroids, vitamin D analogues, calcineurin inhibitors, and keratol

69 Continuing our search for vitamin D analogues, we explored the modification of the

70 Additional adjustment for vitamin D and bisphosphonate use in the previous month r

71 Vitamin D and calcium for the prevention of fracture: a

72 and use of corticosteroids, bisphosphonates, vitamin D and calcium supplements (OR, 1.9; 95% CI, 1.2-

73 r between children receiving 1000 or 2000 IU vitamin D and children receiving 600 IU.

74 ulture systems and animals suggest that both vitamin D and conjugated linoleic acids (CLAs) stimulate

75 indings suggest an interrelationship between vitamin D and intestinal Mn efflux and indicate the impo

76 In this study, we evaluated vitamin D and mineral (iron, zinc, magnesium) transfer t

77 (FGF23) and Klotho, which normally regulate vitamin D and mineral homeostasis, on testicular functio

78 y and indirectly through systemic changes in vitamin D and mineral homeostasis.

79 d trials examining the individual effects of vitamin D and omega-3 (n-3) fatty acid supplementation o

80 The randomized placebo-controlled Vitamin D and Omega-3 Trial suggested a possible benefit

81 A major goal of VITAL (Vitamin D and Omega-3 Trial) was to fill this knowledge

82 men aged 50 years or older in the VITAL-DEP (Vitamin D and Omega-3 Trial-Depression Endpoint Preventi

83 In the rescue experiments, we confirmed vitamin D and VDR inhibited LPS- or activated CD4(+) T c

84 n change in systolic BP with vitamin D vs no vitamin D and with omega-3s vs no omega-3s were both -0.

85 We report evidence for the role of smoking, vitamin D, and BMI in melanoma progression independent o

86 patients with estrogen, metformin, statins, vitamin D, and tumor necrosis factor blockers are uninte

87 evant mechanistic studies regarding n-3 FAs, vitamin D, and vascular disease, and summarize recent me

88 nd our observations from the subjects in the Vitamin D Antenatal Asthma Reduction Trial (VDAART), we

89 using prospectively collected data from the Vitamin D Antenatal Asthma Reduction Trial, a randomized

90 Participants in the vitamin D arm experienced significant improvement in VAS

91 and to explore the potential of circulating vitamin D as a biomarker of exposure in supplementation

92 matory biomarkers, and to assess the role of vitamin D as a potential mediator in the association bet

93 n of patients who reduced the dose of active vitamin D at Month 6 (31% vs. 10% in the placebo group).

94 bility, while phytates and tannins decreased vitamin D bioaccessibility.

95 paring food nanoemulsions, which may enhance vitamin D bioavailability and improve vitamin deficiency

96 issue that expresses VDR that not only makes vitamin D but also can metabolize it to its hormonally a

97 This effect was largely compensated for vitamin D by the fact that this vitamin was more stable

98 a twice-daily MFMD containing added protein, vitamin D, calcium, milk fat globule membrane (phospholi

99 d whole body BMD compared to participants on vitamin D/calcium supplementation and exercise alone.

100 Vitamin D can modulate the innate and adaptive immune sy

101 CC incidence was unrelated to treatment with vitamin D compared with no vitamin D (HR: 0.79; 95% CI:

102 The hazard ratio for vitamin D compared with placebo was 1.01 (95% CI, 0.94,

103 -cause mortality in patients with sufficient vitamin D concentrations (>=50 nmol/L) and a high magnes

104 Rats (N = 38) injected with vitamin D (days 1-3) to induce CVC were infused with sal

105 Vitamin D deficiency (<12 ng/mL) is associated with redu

106 gher body mass index, lower waist-hip ratio, vitamin D deficiency (serum 25-hydroxyvitamin D concentr

107 this study, we examined the hypothesis that vitamin D deficiency (VDD) during early life stage devel

108 The prevalence of vitamin D deficiency (VDD) may be high in countries with

109 ate that about 875,000 older Brazilians have vitamin D deficiency and 7.5 million its insufficiency.

110 Obese children are vulnerable to vitamin D deficiency and impaired cardiovascular health;

111 a strong and independent association between vitamin D deficiency and risk of PCOS in Pakistan, that

112 der adults with a low prevalence of profound vitamin D deficiency at baseline.

113 Vitamin D deficiency causes pro-inflammatory macrophage

114 Vitamin D deficiency has been associated with increased

115 Vitamin D deficiency has been associated with various au

116 Vitamin D deficiency has been linked to various diseases

117 -analysis to obtain the pooled prevalence of vitamin D deficiency in African populations, with use of

118 Correction of vitamin D deficiency in overweight and obese children by

119 Vitamin D deficiency is a major environmental risk facto

120 Mechanisms that can explain why vitamin D deficiency is associated with mobility should

121 Vitamin D deficiency is associated with non-communicable

122 Vitamin D deficiency is associated with obesity-related

123 Vitamin D deficiency is estimated to affect ~40% of the

124 The prevalence of vitamin D deficiency is high in African populations.

125 h frequencies of densitometric osteoporosis, vitamin D deficiency, bone markers abnormalities, and ve

126 nclude efforts to prevent, detect, and treat vitamin D deficiency, especially in newborn babies, wome

127 d intact PTH only among patients with severe vitamin D deficiency.

128 0.31, 0.89) compared with patients who were vitamin D deficient (<50 nmol/L) and had a low magnesium

129 nt mice died earlier (p = 0.003) compared to vitamin D deficient (VDD) mice.

130 The aims were to determine, in vitamin D-deficient overweight and obese children, wheth

131 In a subanalysis of vitamin D-deficient participants, sun exposure was assoc

132 ute respiratory infection than placebo among vitamin D-deficient schoolchildren in Mongolia.

133 25(OH)(2)D levels, and hence, reduces active vitamin D drugs.Clinical Trial Registry: This study was

134 nese, and mercury after supplementation with vitamin D during pregnancy.

135 d markers of systemic inflammation underlies vitamin D effects.

136 Vitamin D exerts a regulatory role over mucosal immunity

137 Vitamin D exerts its actions through the vitamin D recep

138 We hypothesize that more vitamin D exposure (through diet, supplements, and sunli

139 D [25(OH)D] concentration is an indicator of vitamin D exposure, but it is also influenced by clinica

140 r, retinol-binding protein (RBP), 25-hydroxy vitamin D, folate, and vitamin B12; and a panel of immun

141 Ancillary study of The Vitamin D for Established Type 2 Diabetes (DDM2) trial.

142 The Maternal Vitamin D for Infant Growth trial was a randomized, plac

143 the trial was 31.0 ng per milliliter in the vitamin D group and 10.7 ng per milliliter in the placeb

144 A total of 29 children in the vitamin D group and 34 in the placebo group were hospita

145 disease was diagnosed in 21 children in the vitamin D group and in 25 children in the placebo group

146 participants reported >=1 ARI: 74.1% in the vitamin D group versus 73.7% in the placebo group.

147 IU of vitamin D(3) per day during pregnancy (vitamin D group) would have a lower incidence of asthma

148 ent randomization: 4418 were assigned to the vitamin D group, and 4433 to the placebo group; 95.6% of

149 Vitamin D has a key role in stimulating calcium absorpti

150 to treatment with vitamin D compared with no vitamin D (HR: 0.79; 95% CI: 0.49, 1.27), but there was

151 Furthermore, repletion of vitamin D improved skeletal muscle fiber size and in viv

152 Vitamin D improves absorption of calcium; however, in an

153 The bioactivity of vitamin D in hPDLCs was assessed based on the gene expre

154 nalysis were performed to assess any role of vitamin D in mediating a causal effect of BMI on inflamm

155 No interactions between calcium and vitamin D in relation to all-cause mortality were observ

156 associated with inflammation but the role of vitamin D in this process is not clear.

157 The median level of serum vitamin D in those with active uveitis (n = 74) was 46 n

158 the role of calcitriol (active metabolite of vitamin D) in the regulation of Th9 cell differentiation

159 ), we hypothesized that PE, maternal asthma, vitamin D insufficiency, and excess body mass index (BMI

160 However, while we found that vitamin D intake (from diet, supplemental and total) was

161 measurement and completed a questionnaire on vitamin D intake and ultraviolet light exposure.

162 f 25-hydroxyvitamin D (25(OH)D) level and/or vitamin D intake on skin cancer risk are conflicting.

163 We found no associations between vitamin D intake skin cancers, except positive associati

164 Moderate supplemental vitamin D intake was associated with decreased risk of T

165 t associated with risks of melanoma and SCC, vitamin D intake was associated with slightly increased

166 Vitamin D intakes and exposures based on questionnaire r

167 iometabolic risk markers, but double-blinded vitamin D intervention studies in children are scarce.

168 es of a double-blind, randomized, milk-based vitamin D intervention trial conducted during late fall

169 Although vitamin D is critical for the function of the intestine,

170 Vitamin D is produced in the skin.

171 Vitamin D is the precursor to 25(OH)D but is analyticall

172 men with endometriosis, supplementation with vitamin D led to significant changes in pelvic pain; how

173 understanding of the genetic determinants of vitamin D levels by undertaking a large-scale genome-wid

174 This work supports the hypothesis that low vitamin D levels can exacerbate preexisting ophthalmic c

175 showed significantly lower serum 25-hydroxy vitamin D levels than inactive uveitis patients and loca

176 uveitis group also showed lower median serum vitamin D levels than the local population median of 62

177 Serum 25-hydroxy vitamin D levels were compared between active and inacti

178 reported the association of smoking and low vitamin D levels with melanoma death.

179 mong children with persistent asthma and low vitamin D levels, vitamin D3 supplementation, compared w

180 on, regulation of phosphate homeostasis, and vitamin D levels.

181 Activation of liver macrophage VDRs by vitamin D ligands ameliorates liver inflammation, steato

182 nal Nutrition Survey, we defined VDD and low vitamin D (LVD) as serum 25-hydroxyvitamin D [25(OH)D] <

183 r, while experimental evidence suggests that vitamin D may have a protective effect on skin cancer ri

184 Calcium alone or in combination with vitamin D may reduce the risk of SCC, but not BCC.

185 cipants (n = 151) underwent serum 25-hydroxy vitamin D measurement and completed a questionnaire on v

186 conditions.Objectives: To determine whether vitamin D metabolism is altered in asthma or COPD.Method

187 D(3)-to-25(OH)D(3) in serum, suggesting that vitamin D metabolism is dysregulated in these conditions

188 previously been involved in cholesterol and vitamin D metabolism.

189 analysis of 567 older men quantifying serum vitamin D metabolites using LC-MSMS and defining stool s

190 that both dietary and endogenously produced vitamin D metabolites were under polygenic control in Af

191 The benefits of vitamin D, omega-3 fatty acids, and exercise in disease

192 er, data are limited regarding the impact of vitamin D on breast cancer subtypes among African-Americ

193 mega-3 Trial suggested a possible benefit of vitamin D on cancer incidence among black individuals.

194 unknown whether dietary supplementation with vitamin D or calcium prevents keratinocyte carcinomas, a

195 This study aimed to determine whether daily vitamin D or calcium supplementation alters the risk of

196 There was no association of vitamin D or GNRI with mortality at either time.

197 ed to determine whether supplementation with vitamin D or omega-3 fatty acids remediates pain, change

198 daily, aspirin (75 mg) or placebo daily, and vitamin D or placebo monthly.

199 ive protein, albumin, platelet count, 25(OH) vitamin D, or 1,25(di-OH) vitamin D.

200 nd genotpye for 24 SNPs in four genes in the vitamin D pathway (VDR, DBP, CYP27B1, CYP24A1) on PCOS.

201 was not modified by genetic variation in the vitamin D pathway.

202 coded by AD- and psychosis-related genes and Vitamin D-perturbed genes.

203 Vitamin D plus leukemia reprogrammed the marrow increasi

204 Only KTRs not receiving active vitamin D, poor 1,25D status predicted the worse outcome

205 ne, and African Index Medicus for studies on vitamin D prevalence, published from database inception

206 tigations assessing the impact of melanin on vitamin D production have produced contradictory results

207 eded to determine whether differences in the vitamin D-PTH endocrine system contribute to racial disp

208 Vitamin D receptor (VDR) antagonists prevent the VDR act

209 Furthermore, we found vitamin D receptor (VDR) binding sites in the promoters

210 In addition, an association between vitamin D receptor (VDR) gene polymorphisms and diabetes

211 Vitamin D receptor (VDR) is a key genetic factor for sha

212 We show that transgenic expression of the vitamin D receptor (VDR) only in the distal intestine of

213 This is followed by discussion of the vitamin D receptor (VDR) that mediates the cellular acti

214 erator-activated receptor gamma (PPARgamma), vitamin D receptor (VDR), and retinoic acid receptor alp

215 Vitamin D exerts its actions through the vitamin D receptor (VDR), the expression of which was re

216 essed based on the gene expression levels of vitamin D receptor (VDR)-regulated genes osteocalcin and

217 egulatory role over mucosal immunity via the vitamin D receptor (VDR).

218 Treatment with vitamin D receptor agonists (VDRAs) may have nephroprote

219 also describe the expression of a functional vitamin D receptor in IDEC.

220 on using conditional knockout of the myeloid vitamin D receptor in mice (KODMAC).

221 The vitamin D receptor is highly expressed in the gastrointe

222 crophage miR-106b-5p secretion from impaired vitamin D receptor signaling causes inflammation-induced

223 tective effect was associated with increased vitamin D receptor signaling.

224 o calcitriol in their ability to bind to the vitamin D receptor, and most of them exert significantly

225 Vitamin D receptor, oestrogen receptor and mineralocorti

226 marily by lithocholic acid signaling via the vitamin D receptor.

227 tic macrophages express the highest level of vitamin D receptors (VDRs) among nonparenchymal cells, w

228 selected single nucleotide polymorphisms in vitamin D-related genes.

229 ficiency and impaired cardiovascular health; vitamin D replenishment might improve their cardiovascul

230 We studied whether vitamin D repletion could correct aberrant adipose tissu

231 Importantly, vitamin D repletion normalized the expression of those 1

232 Vitamin D repletion stimulated appetite, normalized weig

233 mediator-type drugs, venom immunotherapy, or vitamin D, should be continued.

234 We tested the hypothesis that impaired vitamin D signaling in macrophages causes hypertension u

235 tudy was conducted to study the influence of vitamin D status and genotpye for 24 SNPs in four genes

236 Although adults with low vitamin D status are at increased risk of acute respirat

237 Vitamin D status has increasingly been linked to non-ske

238 st and environmental factors associated with vitamin D status in a cohort of 527 calves from Western

239 Little is known about vitamin D status in older adults in South America, where

240 Altitude was a strong predictor of vitamin D status in this tropical setting.

241 Observational data suggest that low vitamin D status is associated with an increased inciden

242 ommunicable and infectious diseases, but the vitamin D status of African populations is not well char

243 lated conditions, but the role of early life vitamin D status on the development of obesity is poorly

244 Observational studies have linked low vitamin D status to unfavorable cardiometabolic risk mar

245 In addition, we found that neonatal vitamin D status was not predictive of the subsequent de

246 linked maternal asthma, excess BMI, and low vitamin D status with increased risk of Preeclampsia (PE

247 line intestinal or systemic inflammation, or vitamin D status.

248 o test for interactions between genotype and vitamin D status.

249 s with symptoms, markers of inflammation and vitamin D status.

250 ther as a main effect or in interaction with vitamin D status.

251 Vitamin D sufficient mice died earlier (p = 0.003) compa

252 evaluate the effect of different doses of a vitamin D supplement on cardiometabolic risk markers in

253 recommendations regarding calcium intake and vitamin D supplementation after HTx.

254 Vitamin D supplementation also was associated significan

255 acebo injections, in addition to calcium and vitamin D supplementation and standard clinical care.

256 es based on questionnaire results, including vitamin D supplementation and sunlight exposures on week

257 Vitamin D supplementation attenuated expression of key m

258 hether marine omega-3 fatty acid (n-3 FA) or vitamin D supplementation can prevent cardiovascular dis

259 Vitamin D supplementation did not reduce major CVD event

260 Vitamin D supplementation did not result in a lower risk

261 Monthly high-dose vitamin D supplementation does not prevent ARI in older

262 cebo-controlled, multi-arm study of maternal vitamin D supplementation during pregnancy in Dhaka, Ban

263 Vitamin D supplementation during the prenatal period alo

264 olites with T2D and argue against the use of vitamin D supplementation for the prevention of T2D.

265 Whether dosage of vitamin D supplementation has a differential effect on B

266 ction (ARI), randomized controlled trials of vitamin D supplementation have provided inconsistent res

267 ions: Attenuation of the 25(OH)D response to vitamin D supplementation in asthma and COPD associated

268 dies are warranted to examine the effects of vitamin D supplementation in early life on long-term car

269 blem while examining the association between vitamin D supplementation initiated after breast cancer

270 Vitamin D supplementation may have an anti-rhinovirus ef

271 Vitamin D supplementation may prevent falls in older per

272 There was no effect of maternal vitamin D supplementation on asthma and recurrent wheeze

273 supported our findings showing no impact of vitamin D supplementation on inflammatory biomarkers.

274 There was no effect of prenatal vitamin D supplementation on most of the prespecified se

275 om RCTs, do not support a beneficial role of vitamin D supplementation on obesity-related inflammatio

276 Calcium and vitamin D supplementation should be the first step in co

277 reported the results of a trial of prenatal vitamin D supplementation to prevent asthma and recurren

278 om phase 3, randomized, controlled trials of vitamin D supplementation to prevent tuberculosis infect

279 ere triangulated with a literature review of vitamin D supplementation trials.

280 Vitamin D supplementation was associated with lower epig

281 The study aimed to determine if daily vitamin D supplementation with 2000 IU is more effective

282 were able to adhere to statins 1 year after vitamin D supplementation.

283 ing for age, sex, season of measurement, and vitamin D supplementation.

284 ns (233 nm) was ~5.3 times greater than free vitamin D suspension.

285 DESIGN, SETTING, AND PARTICIPANTS: The Vitamin D to Prevent Severe Asthma Exacerbations (VDKA)

286 This enables vitamin D to regulate epidermal differentiation and hair

287 The vitamin D transport efficiency across Caco-2 cells for s

288 illary trial of the Zurich Multiple Endpoint Vitamin D Trial in Knee Osteoarthritis enrolled adults a

289 ht to account for the time-varying nature of vitamin D use and time-varying confounding by bisphospho

290 Vitamin D use was identified from linked prescription da

291 reduction in all-cause mortality in de novo vitamin D users compared with nonusers (hazard ratio (HR

292 ng risk factor for childhood asthma, whereas vitamin D (VD) has emerged as a modifiable prenatal expo

293 Vitamin D (VD) is important in hepatic fibrogenesis in a

294 In sum, our results show that vitamin D/VDR signaling induces miR-27a/b in oral lichen

295 fferences in mean change in systolic BP with vitamin D vs no vitamin D and with omega-3s vs no omega-

296 Low vitamin D was also independently associated with thicker

297 Vitamin D was associated with nonsignificant increases i

298 interactions between the gut microbiome and vitamin D, we conduct a cross-sectional analysis of 567

299 For supplemental vitamin D, we observed possible inverse associations bet

300 o statins and who had low baseline levels of vitamin D were able to adhere to statins 1 year after vi